Onco-nephrology: a decalogue.
Onco-nephrology is an evolving subspecialty that focuses on the complex relationships existing between kidney and cancer. In this opinion piece, we propose a 'decalogue of onco-nephrology', in order to highlight the areas where the nephrologist and oncologist should work closely over the ensuing years to provide cutting-edge care for patients afflicted with cancer and kidney disease. The 10 points we have highlighted include (1) acute kidney injury and chronic kidney disease in cancer patients; (2) nephrotoxic effects of anticancer therapy, either traditional chemotherapeutics or novel molecularly targeted agents; (3) paraneoplastic renal manifestations; (4) management of patients nephrectomized for a kidney cancer; (5) renal replacement therapy and active oncological treatments; (6) kidney transplantation in cancer survivors and cancer risk in ESRD patients; (7) oncological treatment in kidney transplant patients; (8) pain management in patients with cancer and kidney disease, (9) development of integrated guidelines for onco-nephrology patients and (10) clinical trials designed specifically for onco-nephrology. Following these points, a multidisciplinary onco-nephrology team will be key to providing outstanding, cutting-edge care in both the acute and chronic setting to these patients.
Division of Nephrology and Dialysis, Outpatient Clinic of Nephro-Oncology, Istituti Ospitalieri, Cremona, Italy Joint Italian Association of Medical Oncology (AIOM)/Italian Society of Nephrology (SIN) Working Group on Onco-Nephrology, Rome, Italy.
Laura
L
Cosmai
Joint Italian Association of Medical Oncology (AIOM)/Italian Society of Nephrology (SIN) Working Group on Onco-Nephrology, Rome, Italy Division of Medical Oncology, I.R.C.C.S. San Matteo University Hospital Foundation, Pavia, Italy.
Camillo
C
Porta
Joint Italian Association of Medical Oncology (AIOM)/Italian Society of Nephrology (SIN) Working Group on Onco-Nephrology, Rome, Italy Nephrology and Dialysis Unit, San Carlo Borromeo Hospital, University of Milano, Milano, Italy.
Maurizio
M
Gallieni
Department of Internal Medicine, Section of Nephrology, Yale University School of Medicine, New Haven, CT, USA.
Mark A
MA
Perazella
D000970:Antineoplastic Agents / Q000627:therapeutic use; D006801:Humans; D009369:Neoplasms / Q000209:etiology* / Q000517:prevention & control; D009398:Nephrology; D051436:Renal Insufficiency, Chronic / Q000150:complications*
D000970:Antineoplastic Agents
AKI; CKD; cancer; dialysis; nephrectomy; nephrotoxicity